List view / Grid view

Imbruvica (ibrutinib)

 

news

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

18 August 2016 | By The National Institute for Health and Care Excellence (NICE)

In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective. 

news

FDA grants Breakthrough designation to ibrutinib in cGVHD

1 July 2016 | By Victoria White, Digital Content Producer

The US Food and Drug Administration (FDA) has granted a fourth Breakthrough Therapy Designation for ibrutinib (Imbruvica) as monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy.

news

NICE asks Janssen to put ibrutinib forward for the CDF

1 June 2016 | By Victoria White, Digital Content Producer

The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).